Inosine is an alternative carbon source for CD8<sup>+</sup>-T-cell function under glucose restriction.
Wang T, Gnanaprakasam JNR, Chen X, Kang S, Xu X, Sun H, Liu L, Rodgers H, Miller E, Cassel TA, Sun Q, Vicente-Muñoz S, Warmoes MO, Lin P, Piedra-Quintero ZL, Guerau-de-Arellano M, Cassady KA, Zheng SG, Yang J, Yang J, Lane AN, Song X, Fan TW, Wang R. · 2020
Read Inosine is an alternative carbon source for CD8<sup>+</sup>-T-cell function under glucose restriction. by Wang T, Gnanaprakasam JNR, Chen X, Kang S, Xu X, Sun H, Liu L, Rodgers H, Miller E, Cassel TA, Sun Q, Vicente-Muñoz S, Warmoes MO, Lin P, Piedra-Quintero ZL, Guerau-de-Arellano M, Cassady KA, Zheng SG, Yang J, Yang J, Lane AN, Song X, Fan TW, Wang R. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7371628.txt.
Introduction
Wang and co-authors report in Nature Metabolism that killer T cells can run on an alternative fuel called inosine. Active T cells rewire their metabolism to fight infection, but tumors and inflamed tissues can starve them of glucose. The team tested whether inosine, a breakdown product of genetic material, could fill the gap.
Without glucose, T cells grew and worked using inosine, splitting it into a sugar unit that feeds energy pathways. Cancer cells, by contrast, varied widely in using inosine. Adding inosine improved checkpoint drug treatment and cell therapy in solid tumors that could not use it themselves. The trick, in effect, feeds the fighters while the tumor goes hungry. Readers get a neat metabolic lever for immunotherapy.
Catalog record
| CREATOR | Wang T, Gnanaprakasam JNR, Chen X, Kang S, Xu X, Sun H, Liu L, Rodgers H, Miller E, Cassel TA, Sun Q, Vicente-Muñoz S, Warmoes MO, Lin P, Piedra-Quintero ZL, Guerau-de-Arellano M, Cassady KA, Zheng SG, Yang J, Yang J, Lane AN, Song X, Fan TW, Wang R. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 91 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Inosine is an alternative carbon source for CD8+ T cell function under glucose restriction By Tingting Wang, JN Rashida Gnanaprakasam, Xuyong Chen, Siwen Kang, Xuequn Xu, Hua Sun, Lingling Liu, Hayley Rodgers, Ethan Miller, Teresa A. Cassel, Qiushi Sun, Sara Vicente-Muñoz Published in: Nature metabolism DOI: 10.1038/s42255-020-0219-4 ABSTRACT T cells undergo metabolic rewiring to meet their bioenergetic, biosynthetic and redox demands following antigen stimulation. To fulfill these needs, effector T cells must adapt to fluctuations in environmental nutrient levels at sites of infection and inflammation. Here, we show that effector T cells can utilize inosine, as an alternative substrate, to support cell growth and function in the absence of glucose in vitro. T cells metabolize inosine into hypoxanthine and phosphorylated ribose by purine nucleoside phosphorylase (PNP). We demonstrate that the ribose subunit of inosine can enter into central metabolic pathways to provide ATP and biosynthetic precursors, while cancer cells display diverse capacities to utilize inosine as a carbon source. Moreover, the supplement of inosine enhances the anti-tumor efficacy of immune-checkpoint blockade or adoptive T cell transfer in solid tumors that are defective in metabolizing inosine, reflecting the capability of inosine in relieving tumor-imposed metabolic restrictions on T cells. INTRODUCTION A robust adaptive immune response relies on the ability of antigen-specific T cells to rapidly transform from a quiescent (naive) state to a proliferative (active) state, followed by sustained proliferation during the period of antigen presentation. An increasing body of evidence suggests that a coordinated rewiring of cellular metabolism, is required to fulfill the bioenergetic, biosynthetic and redox demands of T cells following activation 1, 2, 3, 4, 5, 6, 7. Naive T cells and memory T cells predominantly rely on fatty acid β-oxidation (FAO) and oxidative phosphorylation (OXPHOS) for their energy supply in the quiescent state. Following antigen stimulation, effector T (Teff) cells rapidly upregulate other pathways including aerobic glycolysis, the pentose phosphate pathway (PPP) and glutaminolysis to drive clonal expansion and effector functions 8, 9, 10, 11. Such metabolic reprogramming induced by T cell activation relies on a hierarchical signaling cascade linking to transcriptional networks 8, 10, 12. It is now commonly recognized that the immune system is intimately involved in tumor initiation, progression, and responses to therapy 13, 14, 15. Teff cells are the major agents to elicit anti-tumor activity through direct recognition and killing of antigen presenting tumor cells as well as orchestrating a plethora of adaptive and innate immune responses 14, 16, 17. However, tumors often co-opt a broad spectrum of mechanisms that foster an immune suppressive microenvironment, thereby escaping T cell-mediated anti-tumor immune response. Various intrinsic and extrinsic tumor factors favor the development of immunosuppressive myeloid-derived suppressor cells (MDSC) and regulatory T (Treg) cells, increasing the expression of inhibitory checkpoint receptors, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and lymphocyte-activation gene 3 (LAG 3); while reducing the expression and presentation of tumor specific antigens 18, 19, 20. Mounting evidence has shown that immunotherapies through strengthening the amplitude and quality of T cell-mediated adaptive response may mediate durable and even complete tumor regression in some cancer patients. Two most promising approaches to enhance therapeutic anti-tumor immunity are immune checkpoint blockade using monoclonal antibodies against PD-1/PDL1 and CTLA4, and adoptive cell transfer (ACT) of tumor infiltrating lymphocytes (TILs) or peripheral T cells that are genetically engineered with chimeric antigen receptors (CARs) 21, 22, 23. Despite the clinical promise of CAR T-cell therapy in B cell leukemia and checkpoint blockade therapies in metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, and others, more than three-quarters of cancer patients overall remain refractory to the current immunotherapeutic regimen 23, 24. To enhance immunotherapeutic efficacy, understanding the key immunosuppressive barriers in cancer tissues is critically important. A key but largely overlooked problem is nutrient competition between tumor cells and T cells in the nutrient poor tumor microenvironment (TME). Metabolic dysregulation is now recognized as one of the hallmarks of human cancer and the activation of oncogenic signaling pathways enabling tumor cells to reprogram pathways of nutrient acquisition and metabolism to meet the additional bioenergetic, biosynthetic and redox demands of cell transformation and proliferation 25, 26, 27. The TME of solid tumors represents a dramatic example of metabolic stress, where the high metabolic demands of cancer cells can restrict the function of Teff cells by competing for nutrients including glucose and by producing immune suppressive metabolites 28, 29, 30, 31, 32. As such, a better understanding of the metabolic modulation of Teff cells to relieve the immunosuppressive barriers in the TME will enable us to devise rational and effective approaches to enhance cancer immunotherapy via improving T cell metabolic fitness. Here, we report that T cells can utilize few substrates, and that inosine is an alternative metabolic substrate that can support cell growth and crucial T cell functions in the absence of glucose in vitro. The catabolism of the ribose subunit of inosine provides both metabolic energy in the form of ATP and biosynthetic precursors from glycolysis and the pentose phosphate pathway. Inosine supplementation promotes T cell-mediated tumor killing activity in vitro and enhances the anti-tumor efficacy of checkpoint blockade therapy or adoptive T cell therapy in certain mouse models, reflecting the capability of inosine in relieving tumor-imposed metabolic restrictions on T cells. RESULTS A metabolic screen identifies inosine as an alternative fuel of T cell in vitro Solid tumors typically develop a hostile microenvironment characterized by an irregular vascular network and a correspondingly poor nutrient supply. Highly glycolytic cancer cells may deplete nutrients, particularly glucose, thereby restricting glucose availability to T cells 28, 29, 30. Previous studies have shown that murine T cells significantly enhanced glucose catabolic activity following activation, and that glucose starvation compromises viability and proliferation of Teff cells 8, 10, 33. We asked whether Teff cells have the capability of taking up alternative carbon and energy sources to support their survival and proliferation in the absence of glucose. To this end, we generated human Teff cells by stimulating human PBMCs with plate-bound anti-CD3 antibody in the presence of interleukin 2 (IL-2). After at least three days activation and expansion of human Teff cells, we plated cells in glucose-free media into 96-well plates (Biolog’s Phenotype MicroArray Mammalian plates PM-M1 and PM-M2) pre-loaded with an array of compounds that can serve as carbon and/or nitrogen sources for mammalian cells. Blank wells and wells pre-loaded with glucose were included as negative and positive controls, respectively. We then determined the substrate utilization of Teff cells in each well through a colorimetric assay in which the formation of the reduced dye represents cells’ ability to catabolize these extracellular substrates and generate NADH. The results were normalized to positive control (wells preloaded with glucose) and summarized in Extended Data Figure 1a. It was found that polysaccharides, six-carbon sugars and their derivatives including dextrin, glycogen, maltotriose, maltose, mannose and fructose-6-phosphate were utilized by Teff cells in the absence of glucose (Extended Data Figure 1a). Remarkably, inosine, a nucleoside, also supported Teff cells bioenergetic activity in the absence of glucose (Extended Data Figure 1a). To eliminate the possibility that inosine was contaminated with glucose or glucose analogs, we obtained inosine from a different source and examined whether inosine could